CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin: Pooled analysis of phase III trials
DOI 10.1055/s-0036-1580780
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Cherney, ME Cooper, S Crowe, OE Johansen, SS Lund, HJ Woerle, UC Broedl, T Hach
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: Glucose lowering with empagliflozin is dependent on renal function. We investigated the influence of chronic kidney disease (CKD) on changes in HbA1c and blood pressure (BP) with empagliflozin. Methods: Using pooled data from five, 24-week randomized Phase III trials in patients with type 2 diabetes (T2DM), we assessed changes from baseline in systolic BP (SBP) and HbA1c with empagliflozin 25 mg versus pl…
Zitieren
Zitierempfehlung
D Cherney, ME Cooper, S Crowe, OE Johansen, SS Lund, HJ Woerle, UC Broedl, T Hach (2016) Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin: Pooled analysis of phase III trials. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580780
Mit CareLit weiterarbeiten